Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel Open-Label Extension in MDD
NCT03668600Phase 3
Key facts
- Status
- Terminated
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Countries
- 1
- Sponsor
- Allergan
- Modality
- Peptides, Small Molecules
- Drugs
- rapastinel
- Conditions
- major depressive disorder (MDD)
01
Overview
Phase 3, open-label, single-arm trial of rapastinel in major depressive disorder (MDD), sponsored by Allergan. Primary endpoint: Treatment Emergent Adverse Events at 45 weeks. Started Aug 2018; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Rapastinel
Rapastinel 450 mg IV
03
Who it enrols
Adult patients with MDD who completed the lead-in study and showed adequate therapeutic benefit without significant suicide risk.
04
Endpoints
Primary
Treatment Emergent Adverse Events
Beyond the preview
Go deeper on NCT03668600.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668600.